Abstracts Archive - Page 1113 of 2607 - ACR Meeting Abstracts

Abstract Number: 2594 • 2019 ACR/ARP Annual Meeting
Associations Between Antibodies to the Angiotensin II Type 1 Receptor and Endothelian-1 Type a Receptor and the Incidence of Vascular Complications in Early Diffuse Systemic Sclerosis
Kendall Downer¹, Robyn Domsic ², Carol Bentlejewski ², Adriana Zeevi ² and Lei Zhu ², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Recently, the hypothesis that autoantibodies to the angiotensin II type 1 (AT1R) and endothelian-1 type A (ETAR) receptors are driving the vascular injury and…
Abstract Number: 2595 • 2019 ACR/ARP Annual Meeting
Asymptomatic Scleroderma Antibody Positivity and Progression to Systemic Sclerosis
Derek Jones ¹, Marissa Mangini ¹, Sydney Wearing ¹ and Victoria Shanmugam², ¹The George Washington University School of Medicine and Health Sciences, Washington, DC, ²George Washington University, Georgetown, DC
Background/Purpose: Systemic sclerosis is an autoimmune disease characterized by inflammation, vasculopathy and fibrosis of the skin, vasculature and internal organs along with disease specific autoantibody…
Abstract Number: 2596 • 2019 ACR/ARP Annual Meeting
The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure
Yoshioki Yamasaki¹, Kanako Suzuki ¹, Keiichi Sakurai ², Yusa Asari ¹, Hidehiro Yamada ³ and Kimito Kawahata ², ¹Rheumatology and Allergology, St. Marianna University School of Medicine, Kawasaki, Japan, ²Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan, ³Center for Rheumatic diseases, Seirei Yokohama Hospital, Kawasaki, Japan
Background/Purpose: Patients with systemic sclerosis (SSc) complicates variety of cardiopulmonary diseases which can result in pulmonary hypertension (PH). The types of PH are usually classified…
Abstract Number: 2597 • 2019 ACR/ARP Annual Meeting
Prevalence and Clinical Associations of Degos Lesions in Systemic Sclerosis
Paula Song¹, Melody Chung ², Shufeng Li ³, David Fiorentino ⁴ and Lorinda Chung ², ¹Department of Medicine, Santa Clara Valley Medical Center, Palo Alto, CA, ²Stanford University, Palo Alto, CA, ³Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA, ⁴Department of Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Degos disease, also known as malignant atrophic papulosis (MAP), is a rare small-vessel vasculopathy that has characteristic cutaneous manifestations consisting of erythematous telangiectatic rims…
Abstract Number: 2598 • 2019 ACR/ARP Annual Meeting
Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Alberto Sulli¹, Federica Goegan ², Emanuele Gotelli ², Massimo Patane' ³, Carmen Pizzorni ³, Sabrina Paolino ³, Elisa Alessandri ⁴ and Barbara Ruaro ⁵, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy
Background/Purpose: Aminaphtone treatment improves clinical symptoms of Raynaud's phenomenon (RP) and increases peripheral blood perfusion (BP) in patients with either primary or secondary RP (1-2).The…
Abstract Number: 2599 • 2019 ACR/ARP Annual Meeting
Body Composition and Nailfold Videocapillaroscopy Patterns in a Cohort of Systemic Sclerosis Patients
Tomatis Veronica ¹, Sabrina Paolino ², Alberto Sulli³, Emanuele Gotelli ⁴, Andrea Casabella ⁵, Francesco Cattelan ⁶, Schenone Carlotta ¹, Carmen Pizzorni ², Elisa Alessandri ⁷ and Maurizio Cutolo ⁸, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, Liguria, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Genoa, Italy, ⁵1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic Hospital San Martino, University of Genoa, Genoa, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease, characterized by microvascular damage and progressive fibrosis. Among clinical complications, abnormal body composition and sarcopenia have been reported…
Abstract Number: 2600 • 2019 ACR/ARP Annual Meeting
‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis
Elena Eusterwiemann¹, Marina Anderson ², Mark Robinson ¹ and Gabor Barton ¹, ¹Liverpool John Moores University, Liverpool, United Kingdom, ²Aintree University Hospital, Liverpool
Background/Purpose: Hand involvement due to increased skin thickness and skin collagen content is one of the first manifestations of systemic sclerosis (SSc) leading to a…
Abstract Number: 2601 • 2019 ACR/ARP Annual Meeting
Trabecular Bone Score and Malnutrition in a Cohort of Systemic Sclerosis Patients
Massimo Patane' ¹, Sabrina Paolino ¹, Veronica Tomatis ², Andrea Casabella ³, Carmen Pizzorni ¹, Luca Carmisciano ⁴, Alessio Signori ⁴ and Maurizio Cutolo⁵, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic Hospital San Martino, University of Genoa, Genoa, Italy.2Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, genova, Liguria, Italy, ³1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by microvascular damage, immune system activation and progressive fibrosis of the skin and internal organs.…
Abstract Number: 2602 • 2019 ACR/ARP Annual Meeting
Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis
Anna Maria Hoffmann-Vold¹, Håvard Fretheim ², Brian Chung ³, Henriette Didriksen ³, Espen Bækkevold ³, Øyvind Midtvedt ³, Cathrine Brunborg ³, Kristian Holm ³, Anders Tennøe ³, Torhild Garen ³, Tore Midtvedt ⁴, Marius Trøseid ³, Johannes Hov ³, Knut Lundin ³ and Øyvind Molberg ², ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²University Hospital Oslo, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: In the double-blind, placebo-controlled 16-week pilot including 10 systemic sclerosis (SSc) patients with upper and lower gastrointestinal (GI) symptoms we found that fecal microbiota…
Abstract Number: 2603 • 2019 ACR/ARP Annual Meeting
Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database
Anna-Maria Hoffmann-Vold¹, Yannick Allanore ², Margarida Alves ³, Nicole Graf ⁴, Paolo Airò ⁵, Lidia P. Ananyeva ⁶, László Czirják ⁷, Serena Guiducci ⁸, Eric Hachulla ⁹, Mengtao Li ¹⁰, Carina Mihai ¹¹, Gabriela Riemekasten ¹², Petros Sfikakis ¹³, Gabriele Valentini ¹⁴, Otylia Kowal-Bielecka ¹⁵ and Oliver Distler ¹⁶, ¹Dept. of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ³Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Graf Biostatistics, Winterthur, Switzerland, Winterthur, Switzerland, ⁵UO Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy, ⁶VA Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, Pécs, Hungary, ⁸Dept. of Clinical and Experimental Medicine, Section of Rheumatology, University of Florence, Italy, Florence, Italy, ⁹Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ¹⁰Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic), ¹¹Dept. of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹²Dept. of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany, Lübeck, Germany, ¹³Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁴Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ¹⁵Dept. of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, Bialystok, Poland, ¹⁶Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The course of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is heterogeneous; some patients may experience rapid decline in lung function, while others have relatively…
Abstract Number: 2604 • 2019 ACR/ARP Annual Meeting
Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis
Caroline Evers ¹, Suzana Jordan ¹, Britta Maurer ¹, Rucsandra Dobrota ¹, Petra Hoederath ² and Oliver Distler³, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Centre for Neurosurgery, Hirslanden, St. Gallen, St. Gallen, Switzerland, ³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Pain is a frequent, yet inadequately explored challenge in patients with systemic sclerosis (SSc). The aim of this study was to conduct an extensive…
Abstract Number: 2605 • 2019 ACR/ARP Annual Meeting
Men and Black Persons Die at Younger Ages from Systemic Sclerosis: A Nationwide Population-based Study
Ram Raj Singh¹, Devanshu Singh ² and Eric Yen ¹, ¹UCLA, Los Angeles, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Systemic sclerosis (SSc) is more common in women than men, but men tend to have a faster disease progression than women. However, conflicting results…
Abstract Number: 2606 • 2019 ACR/ARP Annual Meeting
Evolution of Systemic Sclerosis-Related Interstitial Lung Disease After Autologous Hematopoietic Stem Cell Transplantation
Jacopo Ciaffi¹, Nina van Leeuwen ², Maaike Boonstra ², Lucia Kroft ³, Anne Schouffoer ³, Maarten Ninaber ², Thomas Huizinga ² and Jeska de Vries-Bouwstra ², ¹Leiden University Medical Center, Bologna, Emilia-Romagna, Italy, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Three trials demonstrated the overall superiority of autologous hematopoietic stem cell transplantation (HSCT) compared to pulsed cyclophosphamide (CYC) in SSc. An improvement in forced…
Abstract Number: 2607 • 2019 ACR/ARP Annual Meeting
Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis
Robert Fairchild¹, Melody Chung ¹, Laurel Sharpless ¹, Shufeng Li ² and Lorinda Chung ¹, ¹Stanford University, Palo Alto, CA, ²Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA
Background/Purpose: Systemic Sclerosis (SSc) is a progressive fibrotic and vascular disease affecting multiple organs. Calcinosis cutis in SSc is characterized by calcium deposition in the…
Abstract Number: 2608 • 2019 ACR/ARP Annual Meeting
Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions
David Roofeh¹, Kevin Brown ², Donald Tashkin ³, Shervin Assassi ⁴, Shaney Barratt ⁵, Elana Bernstein ⁶, Nitin Bhatt ⁷, Lorinda Chung ⁸, Harold Collard ⁹, Richard Conway ¹⁰, Paul Dellaripa ¹¹, Christopher Denton ¹², Oliver Distler ¹³, Robyn Domsic ¹⁴, Tracy J. Doyle ¹⁵, Puneet Garcha ¹⁶, Nishant Gupta ¹⁷, Anna Maria Hoffmann-Vold ¹⁸, Vivien Hsu ¹⁹, Francesca Ingegnoli ²⁰, Kerri Johannson ²¹, Bashar Kahaleh ²², Leticia Kawano-Dourado ²³, Ella Kazerooni ¹, Surabhi Khanna ¹⁷, Peter Korsten ²⁴, Celia JF Lin ²⁵, Toby Maher ²⁶, Stephen Mathai ²⁷, Fernando Martinez ²⁸, Eric Matteson ²⁹, Vivek Nagaraja ³⁰, Chester Oddis ³¹, Juan Ovalles-Bonilla ³², John Pauling ³³, Ganesh Raghu ³⁴, Ignasi Rodriguez-Pinto ³⁵, Ivan Rosas ¹⁵, James Seibold ³⁶, Virginia Steen ³⁷, Vibeke Strand ³⁸, Elizabeth Volkmann ³⁹, Dharshan Vummidi ³⁰, Simon Walsh ⁴⁰, Donald Zoz ⁴¹, Athol Wells ⁴² and Dinesh Khanna ⁴³, ¹University of Michigan, Ann Arbor, ²National Jewish Health, Denver, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁵North Bristol NHS Trust, Bristol, England, United Kingdom, ⁶Columbia University, New York City, ⁷Ohio State University Wexner Medical Center, Columbus, ⁸Stanford University, Palo Alto, CA, ⁹University of California San Fransisco, San Fransisco, ¹⁰Blackrock Clinic, Dublin, Ireland, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ¹³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ¹⁴University of Pittsburgh, Pittsburgh, PA, ¹⁵Brigham and Women's Hospital, Harvard Medical School, Boston, ¹⁶Baylor Scott & White Health, Dallas, ¹⁷University of Cincinnati, Cincinnati, ¹⁸Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹⁹Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ²⁰Division of Clinical Rheumatology, ASST Pini-CTO, Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Milan, Italy, Milano, Italy, ²¹University of Calgary, Calgary, ²²University of Toledo, Toledo, OH, ²³University of Sao Paulo, Sao Paulo, Brazil, ²⁴University Medical Center Göttingen, Göttingen, Germany, ²⁵Genentech, San Fransisco, ²⁶National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, ²⁷John Hopkins Pulmonary and Critical Care Medicine, Baltimore, ²⁸Will Cornell Medicine Pulmonary & Critical Care Medicine, New York, ²⁹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ³⁰University of Michigan, Ann Arbor, MI, ³¹University of Pittsburgh Medical Center, Pittsburgh, PA, ³²Hospital Gregorio Marañón, Madrid, Spain, ³³Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, ³⁴University of Washington, Seattle, USA, Seattle, ³⁵University of Barcelona, Barcelona, Spain, ³⁶Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ³⁷Georgetown University, Washington, D.C., USA, Georgetown, ³⁸Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ³⁹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴⁰Kings College London, London, United Kingdom, ⁴¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁴²Royal Bromptom Hospital, London, United Kingdom, ⁴³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Systemic sclerosis associated interstitial lung disease (SSc-ILD) is heterogeneous, with varying degrees of severity and risk of disease progression. No consensus-based definitions of disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].